Sapna Srivastava

Dr. Srivastava has almost 20 years of experience as a senior executive in the biopharmaceutical industry and on Wall Street. Most recently, she was the Chief Financial and Strategy Officer for Abide Therapeutics (acquired by Lundbeck). Prior to Abide, she was the Chief Financial and Strategy Officer for Intellia Therapeutics. She played an integral role in leading the company’s financial operations, private and public equity financings, strategic alliances and direction. Previously, Dr. Srivastava was a senior biotechnology analyst at Goldman Sachs, Morgan Stanley, and ThinkEquity Partners, LLC. She began her career as a research associate at JP Morgan.

She has also served as an independent board member and strategy advisor to several therapeutically focused biotechnology companies and non-profit organizations. She currently serves on the Board of SQZ biotech and Asclepix Therapeutics. Dr. Srivastava received her PhD in neuroscience from New York University and her B.Sc. from St. Xavier’s College in India.